- TRADE NAME: Tudorza Pressair (Forest)
- INDICATIONS: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema
- CLASS: Anticholinergic, Muscarinic antagonist
- HALF-LIFE: 5–8 hours
- FDA APPROVAL DATE: 07/30/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticholinergics
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
